期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 52, 期 4, 页码 1110-1121出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201204964
关键词
Alzheimer's disease; cholesterol; clinical trials; isoprenoids; statins
资金
- Foundation for Science and Technology (FCT), Portugal
- FCT [SFRH/BD/79671/2011, SFRH/BD/79658/2011]
Recent years have seen a significant increase in published data supporting the positive effects of statins on neurodegenerative diseases, in particular on Alzheimers disease. Statins show neuroprotective activity by a combination of different cellular and systemic mechanisms that are based on the inhibition of the biosynthesis of cholesterol and isoprenoid by-products. The promising results obtained in vivo and in epidemiological studies are generally not in accordance with those of placebo-controlled randomized clinical trials. Nevertheless, these results make statins valuable assets for disease prevention rather than therapeutic agents for use when disease symptoms are already displayed. Thus, the modulation of midlife cholesterol and/or statin administration prior to the appearance of dementia or cognitive impairment may have a better long-term outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据